Source comparison
CJC-1295 No DAC vs DAC: Timeline Comparison
Half-life ~30 minutes 6–8 days No DAC requires frequent dosing; DAC allows weekly administration Peak GH elevation 2 hours post-injection 24–48 hours post-injection No DAC mimics natural pulsatile rhythm; DAC creates sustained elevation Dosing frequency 2–3× p
This comparison does not assign a generated winner or score.
- Half-life
- ~30 minutes
- 6–8 days
- No DAC requires frequent dosing; DAC allows weekly administration
- Peak GH elevation
- 2 hours post-injection
- 24–48 hours post-injection
- No DAC mimics natural pulsatile rhythm; DAC creates sustained elevation
- Dosing frequency
- 2–3× per week
- 1× per week or less
- No DAC better preserves receptor sensitivity long-term
- IGF-1 elevation onset
- 7–10 days
- 3–5 days
- DAC produces faster IGF-1 rise but higher risk of desensitization
- Clinical effects timeline
- 2–4 weeks
- 2–3 weeks
- Comparable endpoints, different pharmacokinetic paths
- Receptor downregulation risk
- Low (pulsatile stimulation)
- Moderate to high (continuous elevation)
- No DAC's pulsatile design reduces long-term tolerance risk
- The DAC modification (Drug Affinity Complex) extends circulation time by binding to serum albumin, creating a depot effect that releases the peptide slowly over days. That extended half-life eliminates the need for frequent injections but also eliminates the natural pulsatile GH secretion pattern. Research suggests that continuous GH elevation. While convenient. May lead to receptor desensitization and blunted response after 8–12 weeks, whereas the no-DAC version's pulsatile pattern maintains efficacy across longer study durations. The choice between the two versions depends on protocol priorities: convenience (DAC) versus sustained receptor sensitivity (no DAC).